biote Corp. BTMD
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
biote Corp. (BTMD) is a healthcare company listed in the US with a market value of about $38M. In the twelve months to September 30, 2026 it had revenue of $179M and net income of -$2M, a net margin of -1.1%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is future growth (1/5).
Key numbers: a price to free cash flow of 5.2, a 5-year average ROIC of 95%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% above the current price.
About biote
biote is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $139M in 2021 to $192M in 2025, growth of about 8.4% a year. It was profitable in 4 of the last 5 years in our data. Its share count rose by 355% over three years (dilution for shareholders).
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- 5-year average ROIC above 12%
- Positive free cash flow
- Interest covered more than 5 times
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $179M | $192M | $197M | $185M | $165M | $139M |
| Net income | -$2M | $27M | $3M | $3M | -$969000 | $11M |
| Free cash flow | $7M | $30M | $39M | $27M | -$9M | $32M |
| EPS (diluted) | $-0.07 | $0.74 | $0.09 | $0.13 | $-0.12 | — |
| Net margin | -1.1% | 14.1% | 1.6% | 1.8% | -0.6% | 8.0% |
| ROIC | — | 62.9% | 364.0% | 25.7% | -59.1% | 81.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is biote stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 88% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does biote pay a dividend?
Yes. The dividend yield is about 3.05%, and it has paid dividends for 5 years in our data.
Is biote a good stock to buy?
We do not give buy or sell advice. biote scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.